ONS 41st Annual Congress

CINV impairs quality of life, negatively impacts nutritional status, can delay treatment, elevates the risk of nonadherence to chemotherapeutic therapy, and increases the use of healthcare resources. Therapeutic advances have resulted in better understanding of CINV pathophysiology and how therapy for CINV can be personalized. Join us to learn the most up-to-date therapies for managing CINV as well as expert insights into the pathophysiology and classification of CINV. 

Chair 

Richard J. Gralla, MD, FACP
Professor of Medicine
Albert Einstein College of Medicine
Jacobi Medical Center
Bronx, NY

Faculty

Rebecca Clark-Snow, RN, BSN, OCN
Clinical Nurse Coordinator
The University of Kansas Cancer Center
Westwood, KS

 

Cynthia N. Rittenberg, RN, MN, AOCN, FAAN
Rittenberg Oncology Consulting
Metairie, LA 

This activity is supported by an educational grant from Helsinn Therapeutics (US), Inc. and TESARO.

Please click here to register for this event.